The Drugs Controller General of India on Thursday approved Reliance Life Sciences’ application to conduct clinical trials of its recombinant protein-based COVID-19 vaccine candidate. The approval was provided after the subject expert committee (SEC) reviewed its application during a meeting.
Reliance had sought the regulator’s approval to conduct Phase 1 trial of its two-dose vaccine. Through phase 1, the company wants to obtain information on safety, tolerability, pharmacokinetics and mechanism of action of drugs.
Currently, there are six vaccines that have received emergency use authorisation. Serum Institute’s Covishield, Bharat Biotech’s Covaxin, Russia’s Sputnik V, Moderna’s, Johnson & Johnson’s, and Cadila’s which was approved last week.
Latest Videos
